

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

ANKMY1 RABBIT PAB

货号: S217004 产品全名: ANKMYI 兔多抗 基因符号 ZMYND13 UNIPROT ID: Q9P2S6 (Gene Ac

UNIPROT ID: Q9P2S6 (Gene Accession - BC033495)

背景: ANKMY1 (ankyrin repeat and MYND domain containing 1), also known as ZMYND13 or TSAL1, is a 941 amino acid protein that contains seven ANK repeats, three MORN repeats and one MYND-type zinc finger. MORN repeats were first identified in junctophilins, cytoplasmic proteins involved in junctions between the plasma membrane and the ER/SR membrane. The presence of MORN repeats suggests that ANKMY1 may interact with the plasma membrane. The MYND domain consists of a cluster of cysteine and histidine residues, arranged with an invariant spacing to form a potential zinc-binding motif which may be involved in protein-protein interactions.

抗原: Fusion protein of human ANKMY1

经过测试的应用:ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000 种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human brain tissue using 217004(ANKMY1 Antibody) at a dilution of 1/30(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human brain tissue is first treated with the fusion protein and then with 217004(Anti-ANKMY1 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffinembedded Human thyroid cancer tissue using 217004(Anti-ANKMY1 Antibody) at a dilution of 1/30.



In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and then with D221626(Anti-ANKMY1 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010